BioCryst Pharmaceuticals BCRX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from BioCryst Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's EBITDA margin?
- BioCryst Pharmaceuticals (BCRX) reported EBITDA margin of -42.9% in Q1 2026.
- How has BioCryst Pharmaceuticals's EBITDA margin changed year-over-year?
- BioCryst Pharmaceuticals's EBITDA margin decreased by 726.7% year-over-year, from 6.8% to -42.9%.
- What is the long-term trend for BioCryst Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's EBITDA margin has grown at a -47.5% compound annual growth rate (CAGR), from -976.9% to 39.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.